SEP
DNA icon

Signature Equity Partners’s Ginkgo Bioworks DNA Stock Holding History

Signature Equity Partners’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$178 Hold
29
– – ﹤0.01% 1490
2025
Q4 		$241 Buy
+29
New +$312 ﹤0.01% 1621

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Signature Equity Partners's DNA Position: Q1 2026 in Review

Signature Equity Partners held its Ginkgo Bioworks (DNA) position steady in Q1 2026 at 29 shares worth $178. The position accounts for ﹤0.01% of the portfolio, ranked #1490.

Signature Equity Partners first reported a position in DNA in Q4 2025 and has held it in 2 quarters since. The position peaked at $241 in Q4 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Signature Equity Partners held 29 shares of Ginkgo Bioworks worth $178 as of Q1 2026.
  • Signature Equity Partners left its Ginkgo Bioworks share count unchanged in Q1 2026.
  • Ginkgo Bioworks made up ﹤0.01% of Signature Equity Partners's portfolio in Q1 2026, its #1490 holding.
  • Signature Equity Partners first reported a position in Ginkgo Bioworks in Q4 2025 and has held it in 2 quarters since.
  • Signature Equity Partners's Ginkgo Bioworks position peaked at $241 in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.